ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 152 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2015. The put-call ratio across all filers is 1.77 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $368 | -12.0% | 8,946 | 0.0% | 0.00% | 0.0% |
Q1 2024 | $418 | -2.3% | 8,946 | 0.0% | 0.00% | 0.0% |
Q4 2023 | $428 | -40.3% | 8,946 | -61.7% | 0.00% | 0.0% |
Q3 2023 | $717 | +73.6% | 23,366 | +161.2% | 0.00% | 0.0% |
Q2 2023 | $413 | +15.0% | 8,946 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $359 | -13.3% | 8,946 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $414 | -99.9% | 8,946 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $370,000 | -96.0% | 8,946 | -94.2% | 0.00% | -96.0% |
Q2 2022 | $9,171,000 | -17.8% | 153,716 | 0.0% | 0.05% | -2.0% |
Q1 2022 | $11,163,000 | -13.6% | 153,716 | 0.0% | 0.05% | -3.8% |
Q4 2021 | $12,926,000 | -6.8% | 153,716 | 0.0% | 0.05% | -13.1% |
Q3 2021 | $13,864,000 | +14.4% | 153,716 | +20.9% | 0.06% | +15.1% |
Q2 2021 | $12,124,000 | -16.3% | 127,153 | 0.0% | 0.05% | -22.1% |
Q1 2021 | $14,478,000 | -17.8% | 127,153 | -0.1% | 0.07% | -20.0% |
Q4 2020 | $17,621,000 | +2297.4% | 127,290 | +1322.9% | 0.08% | +2025.0% |
Q3 2020 | $735,000 | +5.0% | 8,946 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $700,000 | +76.3% | 8,946 | 0.0% | 0.00% | +33.3% |
Q1 2020 | $397,000 | +37.4% | 8,946 | +32.1% | 0.00% | +50.0% |
Q4 2019 | $289,000 | -0.3% | 6,773 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $290,000 | -32.6% | 6,773 | 0.0% | 0.00% | -33.3% |
Q2 2019 | $430,000 | -8.5% | 6,773 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $470,000 | +59.9% | 6,773 | 0.0% | 0.00% | +50.0% |
Q4 2018 | $294,000 | -43.1% | 6,773 | 0.0% | 0.00% | -33.3% |
Q3 2018 | $517,000 | -0.8% | 6,773 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $521,000 | +51.0% | 6,773 | 0.0% | 0.00% | +50.0% |
Q1 2018 | $345,000 | +9.9% | 6,773 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $314,000 | -13.0% | 6,773 | 0.0% | 0.00% | -33.3% |
Q3 2017 | $361,000 | -14.3% | 6,773 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $421,000 | -8.3% | 6,773 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $459,000 | -3.6% | 6,773 | 0.0% | 0.00% | -25.0% |
Q4 2016 | $476,000 | -0.8% | 6,773 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $480,000 | +45.0% | 6,773 | 0.0% | 0.00% | +33.3% |
Q2 2016 | $331,000 | -22.8% | 6,773 | 0.0% | 0.00% | -25.0% |
Q1 2016 | $429,000 | -21.1% | 6,773 | +39.6% | 0.00% | -20.0% |
Q4 2015 | $544,000 | +110.9% | 4,850 | +80.9% | 0.01% | +150.0% |
Q3 2015 | $258,000 | -6.2% | 2,681 | 0.0% | 0.00% | 0.0% |
Q2 2015 | $275,000 | – | 2,681 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |